Adipocytes derived from human mesenchymal stem cells (MSCs) are widely used to investigate adipogenesis. Taking into account both the novelty of these MSCs and the scarcity of studies focused on the effects of phenolic compounds, the aim of the present study was to analyze the effect of apigenin, hesperidin and kaempferol on pre-adipocyte and mature adipocytes derived from this type of cells. In addition, the expression of genes involved in TG accumulation was also measured. Pre-adipocytes were cultured from day 0 to day 8 and mature adipocytes for 48 h with the polyphenols at doses of 1, 10 and 25 µM. Apigenin did not show an anti-adipogenic action. Pre-adipocytes treated with hesperidin and kaempferol showed reduced TG content at the three experimental doses. Apigenin did not modify the expression of the main adipogenic genes (c/ebpβ, c/ebpα, pparγ and srebp1c), hesperidin inhibited genes involved in the three phases of adipogenesis (c/ebpβ, srebp1c and perilipin) and kaempferol reduced c/ebpβ. In mature adipocytes, the three polyphenols reduced TG accumulation at the dose of 25 µM, but not at lower doses. All compounds increased mRNA levels of atgl. Apigenin and hesperidin decreased fasn expression. The present study shows the anti-adipogenic effect and delipidating effects of apigenin, hesperidin and kaempferol in human adipocytes derived from hMSCs. While hesperidin blocks all the stages of adipogenesis, kaempferol only inhibits the early stage. Regarding mature adipocytes, the three compounds reduce TG accumulation by activating, at least in part, lipolysis, and in the case of hesperidin and apigenin, also by reducing lipogenesis. The present study shows for the first time the anti-adipogenic effect and delipidating effect of apigenin, hesperidin and kaempferol in human adipocytes derived from MSCs for the first time.
Quercetin (Q) has rapid metabolism, which may make it worthwhile to focus on the potential activity of its metabolites. Our aim was to evaluate the triglyceride-lowering effects of Q metabolites in mature and pre-adipocytes, and to compare them to those induced by Q. 3T3-L1 mature and pre-adipocytes were treated with 0.1, 1 and 10 µM of Q, tamarixetin (TAM), isorhamnetin (ISO), quercetin-3-O-glucuronide (3G), quercetin-3-O-sulfate (3S), as well as with 3S and quercetin-4-O-sulfate (4S) mixture (3S+4S). Triglyceride (TG) content in both cell types, as well as free fatty acid (FFA) and glycerol in the incubation medium of mature adipocytes were measured spectrophotometrically. Gene expression was assessed by RT-PCR. In mature adipocytes, Q decreased TG at 1 and 10 µM, 3S metabolite at 1 and 10 µM, and 3S+4S mixture at 10 µM. 3S treatment modified the glucose uptake, and TG assembling, but not lipolysis or apoptosis. During differentiation, only 10 µM of ISO reduced TG content, as did Q at physiological doses. In conclusion, 3S metabolite but not ISO, 3G, 4S and TAM metabolites can contribute to the in vivo delipidating effect of Q.
Several studies have observed that gut microbiota can play a critical role in nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) development. The gut microbiota is influenced by different environmental factors, which include diet. The aim of the present review is to summarize the information provided in the literature concerning the impact of changes in gut microbiota on the effects which dietary fat has on liver steatosis in rodent models. Most studies in which high-fat feeding has induced steatosis have reported reduced microbiota diversity, regardless of the percentage of energy provided by fat. At the phylum level, an increase in Firmicutes and a reduction in Bacteroidetes is commonly found, although widely diverging results have been described at class, order, family, and genus levels, likely due to differences in experimental design. Unfortunately, this fact makes it difficult to reach clear conclusions concerning the specific microbiota patterns associated with this feeding pattern. With regard to the relationship between high-fat feeding-induced changes in liver and microbiota composition, although several mechanisms such as alteration of gut integrity and increased permeability, inflammation, and metabolite production have been proposed, more scientific evidence is needed to address this issue and thus further studies are needed.
Background: Aging is the main risk factor for Alzheimer’s disease (AD). Several approved drugs currently used to treat conditions such as high blood pressure and diabetes may also influence the aging process, holding significant potential to delay AD onset or its progression. Method: Longitudinal samples from a Swedish twin cohort (N=672) were used to assess the effects of commonly prescribed medications on biological aging. Causal inference methods were further applied on genotype and National Register data to search for drug candidates with preventive effects on AD and dementia. The identified classes of compounds were evaluated for their ability to prevent aging and thereby extend lifespan in C. elegans , for their ability to defer paralysis and uncoordinated movement in C. elegans models expressing amyloid beta (Aβ) and tau, for their ability to lower Aβ levels in neuroblastoma SH‐SY5Y cells, and for their ability to ameliorate AD‐associated pathologies in
App
NL‐F knock‐in mice and human tau knock‐in mice. Results: We found that use of calcium channel blockers (CCBs) was associated with about a two‐year decrease in multiple epigenetic clocks (DNA methylation ages) and functional aging. Moreover, genetic variants in the glucagon‐like peptide 1 (GLP‐1) gene were associated with lower risk of developing AD, and patients on GLP‐1 analogue treatment had a lower risk of dementia. Several of the clinically used CCBs and GLP‐1 analogues significantly increased the life span in C. elegans and decreased levels of secreted Aβ from SH‐SY5Y cells. Exposing C. elegans to these compounds throughout adulthood didn’t suppress the Aβ‐induced paralysis. However, several CCBs and GLP‐1 analogues had the ability to delay uncoordinated movements in the C. elegans tau model. Conclusion: Further perspectives : Next steps include treating
App
NL‐F knock‐in mice and human tau mice with the most promising drug candidates. Biochemical and histological analyses, including immunohistochemistry, will be employed to assess reductions in Aβ and tau pathologies, neuroinflammation, and synaptic alterations. This work explores the potential of repurposing aging‐preventive drugs for the prevention or delay of Alzheimer’s disease, potentially creating a new strategy to target AD.